Additional file 2: of Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016 IkedaSatoshi KatoTerufumi OguraTakashi SekineAkimasa OdaTsuneyuki MasudaNoriyuki IgawaSatoshi KatonoKen OtaniSakiko YamadaKouzo SaitoHaruhiro KondoTetsuro HosomiYukio NakaharaYoshiro NishikawaMasanori UtumiKeiko MisumiYuki YamanakaTakeharu SakamakiKentaro OkamotoHiroaki 2018 Table S1. CEC data and treatment efficacy of 35 patients whose CEC count was measured on days 1 and 8. Abbreviations: EGFR, epidermal growth factor receptor; CEC, circulating endothelial cell; PR, partial response; SD, stable disease; PFS, progression-free survival; OS, overall survival. (DOCX 22 kb)